- Home
- CAPR
as 12-20-2024 4:00pm EST
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | BEVERLY HILLS |
| Market Cap: | 867.6M | IPO Year: | N/A |
| Target Price: | $39.29 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.52 - $23.40 | Next Earning Date: | 11-13-2024 |
| Revenue: | $23,228,045 | Revenue Growth: | 65.33% |
| Revenue Growth (this year): | -32.05% | Revenue Growth (next year): | 74.85% |
Latest Capricor Therapeutics Inc. News
CAPR Breaking Stock News: Dive into CAPR Ticker-Specific Updates for Smart Investing
Simply Wall St.
10 days ago
High Growth Tech Stocks To Watch In December 2024
GlobeNewswire
20 days ago
Capricor Therapeutics to Present at Upcoming Investor Conferences
MT Newswires
a month ago
Capricor Gets Orphan Drug, Advanced Therapy Medicinal Product Designations for Deramiocel in Europe
GlobeNewswire
a month ago
Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency
MT Newswires
a month ago
JonesTrading Initiates Capricor Therapeutics at Buy Rating With $40 Price Target
Insider Monkey
a month ago
Is Capricor Therapeutics (CAPR) the Best Multibagger Stock to Buy Heading into 2025?
Simply Wall St.
a month ago
Capricor Therapeutics Third Quarter 2024 Earnings: Misses Expectations
Thomson Reuters StreetEvents
a month ago
Q3 2024 Capricor Therapeutics Inc Earnings Call
Compare CAPR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CAPR Capricor Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.